ACHV
ACHIEVE LIFE SCIENCES, INC.Company Information
- Company Name
- ACHIEVE LIFE SCIENCES, INC.
- CIK
- CIK0000949858
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- ACHV: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2835
- SIC Description
- In Vitro & In Vivo Diagnostic Substances
- Ticker
- ACHV
SEC filing data through
Insider Sentiment
- Last purchase
- 2025-03-17
- Last sale
- 2025-09-18
- Shares purchased (TTM)
- 20,000
- Shares sold (TTM)
- 381,972
Institutional Sentiment
- As of
- 2026-03-31
- Institutional shares owned
- 21,491,189
- Shares outstanding
- 53,381,989
- Ownership
- 40.26%
Earnings Market Reaction
- Filing date
- 2026-08-11
- Price on filing date
- —
- 1-month reaction
- 25.41%
- 3-month reaction
- Pending
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 48 | 28 | 21 | 32 | 52 | 13 | 13 | 10 | 15 | 66 | 16 | 20 | ||||||
| Grants Receivable Current | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Short Term Investments | - | - | - | - | - | - | - | 33 | 47 | - | - | - | ||||||
| Marketable Securities Current | 139 | 1 | 15 | 16 | 4 | 10 | 22 | - | - | - | - | - | ||||||
| Prepaid Expense And Other Assets Current | - | - | - | 2 | 2 | 2 | 2 | 3 | 1 | 1 | 1 | 2 | ||||||
| Assets Current | 188 | 31 | 40 | 50 | 57 | 25 | 36 | 46 | 63 | 68 | 17 | 22 | ||||||
Assets Noncurrent | ||||||||||||||||||
| Operating Lease Right Of Use Asset | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Other Intangible Assets Net | 0 | - | - | - | - | - | - | - | - | - | - | - | ||||||
| Finite Lived Intangible Assets Net | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Goodwill | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Assets | 190 | 33 | 42 | 52 | 59 | 27 | 39 | 48 | 65 | 70 | 19 | 24 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | - | - | - | 2 | 1 | 2 | 2 | 1 | 1 | 0 | 1 | 1 | ||||||
| Other Accrued Liabilities Current | - | - | - | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | ||||||
| Business Combination Contingent Consideration Liability | - | - | - | - | - | - | - | 1 | 1 | 1 | 1 | - | ||||||
| Employee Related Liabilities Current | 3 | 2 | 2 | 2 | 2 | 1 | 3 | 2 | 1 | 1 | 2 | 2 | ||||||
| Business Combination Contingent Consideration Liability Current | 1 | 0 | 2 | 1 | 1 | - | 0 | - | - | - | 1 | - | ||||||
| Operating Lease Liability Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Convertible Debt Current | 7 | 6 | 4 | 1 | 1 | 1 | - | - | 9 | 17 | 17 | - | ||||||
| Liabilities Current | 198 | 12 | 9 | 10 | 9 | 7 | 7 | 7 | 14 | 21 | 21 | 4 | ||||||
| Convertible Debt Noncurrent | 7 | 9 | 11 | 9 | 9 | 9 | 10 | 10 | 9 | - | - | 16 | ||||||
| Business Combination Contingent Consideration Liability Noncurrent | - | 1 | 0 | 0 | 0 | 1 | 1 | - | - | - | - | - | ||||||
| Operating Lease Liability Noncurrent | - | - | 0 | 0 | 0 | 0 | 0 | - | - | - | 0 | 0 | ||||||
| Liabilities | 205 | 22 | 20 | 18 | 17 | 17 | 18 | 17 | 23 | 21 | 21 | 20 | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital Common Stock | 330 | 281 | 282 | 279 | 273 | 229 | 226 | 224 | 223 | 222 | 164 | 164 | ||||||
| Retained Earnings Accumulated Deficit | -345 | -270 | -260 | -246 | -231 | -218 | -206 | -193 | -181 | -172 | -166 | -160 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0 | 0 | 0 | 0 | ||||||
| Stockholders Equity | -15 | 11 | 22 | 34 | 42 | 10 | 21 | 31 | 42 | 49 | -1 | 4 | ||||||
| Liabilities And Stockholders Equity | 190 | 33 | 42 | 52 | 59 | 27 | 39 | 48 | 65 | 70 | 19 | 24 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | ||||||
| Common Stock Shares Issued | 103 | 53 | 53 | 53 | 50 | 35 | 35 | 34 | 34 | 34 | 21 | 21 | ||||||
| Shares Outstanding | 103 | 53 | 53 | 53 | 50 | 35 | 35 | 34 | 34 | 34 | 21 | 21 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialACHIEVE LIFE SCIENCES, INC. (ACHV) — SEC Financial Statements & Analysis
ACHIEVE LIFE SCIENCES, INC. (ACHV) is a in vitro & in vivo diagnostic substances company, incorporated in DE. ACHIEVE LIFE SCIENCES, INC. trades on Nasdaq as: ACHV. ACHIEVE LIFE SCIENCES, INC. (ACHV)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-11. Based on that filing, ACHIEVE LIFE SCIENCES, INC. carries a market cap of $610.62M, a P/E ratio of -5.35x, a P/B ratio of -41.61x, an enterprise value of $577.58M, and an EV/EBITDA multiple of -5.03x. On profitability, it posts a Return on Equity (ROE) of -844.99%, a Return on Assets (ROA) of -91.46%, and a Return on Invested Capital (ROIC) of -331.53%. Per share, it reports EPS of $-1.22, diluted EPS of $-1.22, free cash flow per share of $-0.50, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of 126.19% year-over-year and EPS growth of -16.10% year-over-year. On the balance sheet, it maintains a current ratio of 0.95x, a quick ratio of 0.95x, working capital of $-9.36M, a debt-to-equity ratio of -13.98x, a debt ratio of 1.08, an interest coverage ratio of -115.73x, free cash flow of $-47.03M (TTM), and net debt of $-33.05M. Figures sourced from SEC EDGAR.
- Market Cap
- $610.62M
- P/E TTM
- -5.35x
- EPS TTM
- $-1.22
- P/B TTM
- -41.61x
- ROE TTM
- -844.99%
- ROA TTM
- -91.46%
- Debt To Equity
- -13.98x
- Free Cash Flow TTM
- $-47.03M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is ACHIEVE LIFE SCIENCES, INC. in?
ACHIEVE LIFE SCIENCES, INC. (ACHV) operates in the In Vitro & In Vivo Diagnostic Substances industry.
What exchange does ACHV trade on?
ACHIEVE LIFE SCIENCES, INC. (ACHV) trades on the Nasdaq.
Where is ACHIEVE LIFE SCIENCES, INC. incorporated?
ACHIEVE LIFE SCIENCES, INC. is incorporated in DE.
When was ACHIEVE LIFE SCIENCES, INC. (ACHV)'s most recent SEC filing?
ACHIEVE LIFE SCIENCES, INC. (ACHV)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-11.
What is ACHV's market cap?
ACHIEVE LIFE SCIENCES, INC. (ACHV) has a market capitalization of $610.62M as of 2026-06-30.
What is ACHV's EPS (earnings per share)?
ACHIEVE LIFE SCIENCES, INC. (ACHV)'s trailing twelve month EPS is $-1.22 as of 2026-06-30.
What is ACHV's ROE (return on equity)?
ACHIEVE LIFE SCIENCES, INC. (ACHV)'s trailing twelve month Return on Equity (ROE) is -844.99% as of 2026-06-30.
What is ACHV's ROA (return on assets)?
ACHIEVE LIFE SCIENCES, INC. (ACHV)'s trailing twelve month Return on Assets (ROA) is -91.46% as of 2026-06-30.
What is ACHV's ROIC (return on invested capital)?
ACHIEVE LIFE SCIENCES, INC. (ACHV)'s trailing twelve month Return on Invested Capital (ROIC) is -331.53% as of 2025-12-31.
What is ACHV's EV/EBITDA?
ACHIEVE LIFE SCIENCES, INC. (ACHV)'s trailing twelve month EV/EBITDA is -5.03x as of 2026-06-30.